Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Yeh C, Zhou M, Bapodra N, Rivero M, Espinal-Dominguez E, Moran M, Hershman DL, Fojo T, Bates SE June 6, 2022 ASCO 2022 Breast Cancer

A Novel Analysis of Data From the PALOMA-3 Trial Confirms the Efficacy of Palbociclib and Provides an Option for Efficacy Assessments that Could Accelerate Drug Approvals

View Presentation View Abstract Plain Language Summary
Poster
Pascual J, Martin M,   Proszek P,   Gil-Gil M,   Reay A,   Zielinski C,   Herranz J, Cutts R, Ruiz-Borrego M, Feber A, Ciruelos EM, Swift C, Munoz M, Bermejo B, Margeli M, Li Y, García-Murillas I,   Hubank M, Turner NC June 6, 2022 ASCO 2022 Breast Cancer

Baseline and Longitudinal ctDNA Biomarkers in GEICAM/2013-02 (PEARL) Trial Cohort 2 Comparing Palbociclib and Fulvestrant (PAL + FUL) versus Capecitabine (CAPE)

View Presentation
Poster
Hu X, Broughton E, Li W, Sun T, Shen K, Huang C-S, Sriuranpong V, Ngan KCR, Chia YH, Bhattacharyya H, Zhao H, Shen J, Xu B September 10, 2022 ESMO 2022 Breast Cancer

Patient-Reported Quality of Life in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole: Results From PALOMA-4

View Presentation View Abstract Plain Language Summary
Poster
Tripathy D, Rocque GB, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi M, Anderson D, Gauthier E, Zhang Z, Montelongo MZ, Wang Y September 10, 2022 ESMO 2022 Breast Cancer

Real-World Clinical Outcomes of Palbociclib Plus Endocrine Therapy in Hormone Receptor–Positive Advanced Breast Cancer: Results From the POLARIS Trial

View Presentation View Abstract Plain Language Summary
Poster
Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D September 10, 2022 ESMO 2022 Breast Cancer

Real-World Quality of Life in Patients With HR+/HER2– Advanced Breast Cancer Treated With Palbociclib: Final Clinical Outcome Assessment Analysis From POLARIS

View Presentation View Abstract Plain Language Summary
Poster
Karam J, Rejto P, Bienkowska JR, Mu XJ, Roh W April 18, 2023 AACR 2023 Breast Cancer

Identification of Tumor-Specific Breast Cancer Expression Subtypes and Subtype-Specific Drug Response Prediction

View Presentation